Rothschild Investment LLC Has $7.03 Million Position in Kenvue Inc. (NYSE:KVUE)

Rothschild Investment LLC reduced its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 9.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 293,301 shares of the company's stock after selling 28,901 shares during the period. Rothschild Investment LLC's holdings in Kenvue were worth $7,033,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Handelsbanken Fonder AB boosted its position in shares of Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock valued at $15,846,000 after acquiring an additional 21,222 shares in the last quarter. Alberta Investment Management Corp lifted its holdings in Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock valued at $12,445,000 after purchasing an additional 109,700 shares during the last quarter. Longbow Finance SA lifted its holdings in Kenvue by 5.0% during the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Kenvue by 143.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after purchasing an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. lifted its holdings in Kenvue by 1.4% during the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after purchasing an additional 17,466 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 0.9%

Shares of KVUE traded down $0.21 on Monday, reaching $23.67. 9,774,685 shares of the company's stock were exchanged, compared to its average volume of 16,319,737. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.41 billion, a P/E ratio of 44.65, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The business has a 50 day moving average price of $23.27 and a two-hundred day moving average price of $22.63. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 earnings per share. Research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on KVUE shares. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays lifted their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday, May 12th. UBS Group lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Citigroup lifted their price target on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a report on Friday, May 9th. Finally, Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.